Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Sponsor: Leiden University Medical Center
Summary
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Official title: Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
400
Start Date
2023-01-01
Completion Date
2027-12-31
Last Updated
2026-02-13
Healthy Volunteers
No
Conditions
Interventions
SGLT2 inhibitors
Treatment with any type and dose of sodium-glucose cotransporter 2 inhibitor.
Locations (11)
Johns Hopkins University
Baltimore, Maryland, United States
Helen DeVos Children's Hospital
Grand Rapids, Michigan, United States
Mount Sinai Fuster Heart Hospital
New York, New York, United States
Heart Center Duisburg (Evangelical Hospital Niederrhein)
Duisburg, Germany
Leiden University Medical Center (LUMC)
Leiden, South Holland, Netherlands
Amsterdam University Medical Center
Amsterdam, Netherlands
University Medical Center Utrecht
Utrecht, Netherlands
Zan Mitrev Clinic
Skopje, North Macedonia
University Hospital of Wales
Cardiff, United Kingdom
Golden Jubilee University National Hospital
Glasgow, United Kingdom
Barts Heart Centre
London, United Kingdom